Patent US5437861A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5437861A Expired / Lapsed US ⏱️ 0.0 years remaining

Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome

Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1993-03-16
•
Granted: 1995-08-01
•
Expires: 2013-03-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention provides a composition, device and method for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood.

Inventors

  • 👤 Thomas B. Okarma
  • 👤 John Blankenship
  • 👤 Abraham T. Lin
  • 👤 Mohammad A. Elkalay

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 01:17
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61M1/34; A61M1/342; A61M1/3424; A61M1/3431; A61M1/3621; A61M1/3643; A61M1/3644; A61M1/3672; A61M1/3673; Y; Y10; Y10S; Y10S530/00; Y10S530/81; Y10S530/811

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 78 words
A composition of matter comprising amorphous, particulate, non-spherical silica and a silica pretreating agent wherein the silica pretreating agent is substantially devoid of covalent attachment to the silica, wherein the silica has a specific surface area between 150 m 2 /g and 600 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, and wherein the silica pretreating agent is heparin or albumin; and wherein the composition is capable of removing selected factors from blood.
Claim 2
Dependent Claim 78 words
A composition of matter comprising amorphous, particulate, non-spherical silica and a silica pretreating agent wherein the silica pretreating agent is substantially devoid of covalent attachment to the silica, wherein the silica has a specific surface area between 150 m 2 /g and 600 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, and wherein the silica pretreating agent is heparin or albumin; and wherein the composition is capable of removing selected factors from blood.
Claim 3
Dependent Claim 24 words
The composition of claim 1 wherein the specific surface area of the silica is between 150 m 2 /g and 1000 m 2 /g.
Claim 4
Dependent Claim 24 words
The composition of claim 2, wherein the specific surface area of the silica is between 200 m 2 /g and 600 m 2 /g.
Claim 5
Dependent Claim 18 words
The composition of claim 1 wherein the porosity of the silica is between 0.8 cc/g and 1.5 cc/g.
Claim 6
Dependent Claim 12 words
The composition of claim 1 wherein the silica is substantially unmodified chemically.
Claim 7
Dependent Claim 19 words
The composition of claim 1 in which the silica particles have a mean diameter less than about 1 mm.
Claim 8
Dependent Claim 20 words
The composition of claim 1 in which the silica particles have a mean diameter between about 50 and 250 microns.
Claim 9
Dependent Claim 21 words
The composition of claim 1 in which the silica has a mean pore diameter of about 30 Å to 300 Å.
Claim 10
Dependent Claim 21 words
The composition of claim 8 in which the silica has a mean pore diameter of about 60 Å to 200 Å.
Claim 11
Dependent Claim 23 words
The composition of claim 1 in which the human serum albumin comprises between 1% and 25% by weight of the silica pretreating agent.
Claim 12
Dependent Claim 21 words
The composition of claim 10 in which the human serum albumin comprises between 2.5% and 5% of the silica pretreating agent.
Claim 13
Dependent Claim 21 words
The composition of claim 1 in which the selected factors comprise cytokines, complement molecules, serotonin, histamine, cholesterol molecules, or angiogenesis factor.
Claim 14
Dependent Claim 28 words
The composition of claim 1, wherein the composition is comprised within a porous solid matrix, and wherein the composition is substantially devoid of covalent attachment to the matrix.
Claim 15
Dependent Claim 18 words
The composition of claim 1 contained within an article, the article comprising a means for retaining the composition.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-07-31 1999-01-30 1999-08-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-07-31 2003-01-30 2003-08-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-07-31 2007-01-30 2007-08-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag